Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters

Drug Metabolism Reviews

Volumn 42, Issue 3, 2010, Pages 539-550

  Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug drug interaction; Efflux; Hepatobiliary transport; Induction; Intrahepatic diffusion; Physiologically based pharmacokinetic modeling; Rate determining process; Transporter; Uptake

Indexed keywords

ATORVASTATIN; BOSENTAN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CEFODIZIME; CYCLOSPORIN A; CYTOCHROME P450 1A; CYTOCHROME P450 3A; DEXAMETHASONE; DIBROMOSULFOPHTHALEIN; ESTRADIOL; FEXOFENADINE; INDOCYANINE GREEN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; OLMESARTAN; OMEPRAZOLE; ORGANIC ANION TRANSPORTER 1; PHENOBARBITAL; PITAVASTATIN; PRAVASTATIN; PROBENECID; RIFAMPICIN; ROSUVASTATIN; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN; DRUG;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTERACTION; DRUG LIVER LEVEL; DRUG TRANSPORT; DRUG UPTAKE; ENZYME INDUCTION; FIRST PASS EFFECT; GENETIC POLYMORPHISM; HEPATOBILIARY SYSTEM; HUMAN; INTRAHEPATIC BILE DUCT; LIVER CELL; LIVER SINUSOID; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; NONHUMAN; PROCESS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ACTIVE TRANSPORT; ALGORITHM; ANIMAL; BILE; BIOLOGICAL MODEL; LIVER; METABOLIC CLEARANCE RATE; METABOLISM; PHARMACOKINETICS; STATISTICAL MODEL;

ALGORITHMS; ANIMALS; BILE; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; DRUG INTERACTIONS; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 77954355830     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602530903491824     Document Type: Review

References (50)

1. Abe, K., Bridges, A. S., Yue, W., Brouwer, K. L. (2008). In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ter 326:983-990
2. Backman, J. T., Luurila, H., Neuvonen, M., Neuvonen, P. J. (2005). Rifampin markedly decreases and gemfbrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ter 78:154-167.
3. Fromm, M. F., Kaufmann, H. M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., et al. (2000). Te efect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580.
4. Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M., Tamai, I. (2008). Efect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepato-cytes. Drug Metab Dispos 36:1275-1282.
5. Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
6. Giacomini, K. M., Sugiyama, Y. (2005). Membrane transporters and drug response. In: Brunton, L. L., Lazo, J. S., Parker, K. L., Goodman, L. S., Gilman, A. G. (Eds.), Goodman & Gilman's Te Pharmacological Basis of Terapeutics, 11th ed. (pp 41-70), McGraw-Hill Professional Publishing: New York, USA.
7. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., et al. (1999) Te role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
8. Hirano, M., Maeda, K., Shitara, Y., Sugiyama, Y. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ter 311:139-146.
9. Hirano, M., Maeda, K., Shitara, Y., Sugiyama, Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34:1229-1236.
10. Hubbard, A. L., Barr, V. A., Scott, L. J. (1994). Hepatocyte surface polarity. In: Arias, I., Wolkof, A., Boyer, J., Shafritz, D., Fausto, N., Jakoby, W. B., et al. (Eds.), Te liver: biology and pathobiology. New York: Raven Press.
11. Igel, M., Arnold, K. A., Niemi, M., Hofmann, U., Schwab, M., Lutjohann, D., et al. (2006). Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efcacy of multiple-dose pravastatin. Clin Pharmacol Ter 79:419-426.
12. Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., et al. (2006). Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109-1115.
13. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ter 73:147-171.
14. Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., et al. (2002). Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors, preg-nane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908-2915.
15. Kato, M., Chiba, K., Horikawa, M., Sugiyama, Y. (2005). Te quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236-243.
16. Kawai, R., Lemaire, M., Steimer, J. L., Bruelisauer, A., Niederberger, W., Rowland, M. (1994). Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22:327-365.
17. Kitamura, Y., Hirouchi, M., Kusuhara, H., Schuetz, J. D., Sugiyama, Y. (2008). Increasing systemic exposure of methotrexate by active efux mediated by multidrug resistance-associated protein 3 (Mrp3/Abcc3). J Pharmacol Exp Ter 327:465-473.
18. Klaassen, C. D., Slitt, A. L. (2005). Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6:309-328.
19. Kusuhara, H., Sugiyama, Y. (2009). In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
20. Kyrklund, C., Backman, J. T., Neuvonen, M., Neuvonen, P. J. (2004). Efect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 57:181-187.
21. Lau, Y. Y., Huang, Y., Frassetto, L., Benet, L. Z. (2007). Efect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ter 81:194-204.
22. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. (2008). SLCO1B1 variants and statin-induced myopathy\a genomewide study. NEJM 359:789-799.
23. 2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ter 289:1592-1599. (Pubitemid 29246695)
24. Maeda, K., Sugiyama, Y. (2008). Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic, and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23:223-235.
25. Matsushima, S, Maeda, K, Hayashi, H, Debori, Y, Schinkel, AH, Schuetz, JD, et al. (2008a). Involvement of multiple efux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483.
26. Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T., Sugiyama, Y. (2008b). Investigation of the inhibitory efects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669.
27. Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., et al. (2005). Identifcation of the hepatic efux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ter 314:1059-1067.
28. McCuskey, R. S. (1992). Functional morphology of the liver with empahsis on microvasculature. In: Tavoloni, N., Berk, P. D. (Eds.), Hepatic transport and bile secretion: physiology and pathophysi-ology. New York: Raven Press.
29. Milne, R. W., Larsen, L. A., Jorgensen, K. L., Bastlund, J., Stretch, G. R., Evans, A. M. (2000). Hepatic disposition of fexofenadine: infu-ence of the transport inhibitors, erythromycin and dibromosul-phothalein. Pharm Res 17:1511-1515.
30. Muck, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., et al. (1999). Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ter 65:251-261.
31. Niemi, M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802.
32. Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M., Lutjohann, D., et al. (2005). Acute efects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genom 15:303-309.
33. Nies, A. T., Schwab, M., Keppler, D. (2008). Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efux pumps in the elimination of drugs. Exp Opin Drug Metab Toxicol 4:545-568.
34. Niinuma, K., Kato, Y., Suzuki, H., Tyson, C. A., Weizer, V., Dabbs, J. E., et al. (1999). Primary active transport of organic anions on bile canalicu-lar membrane in humans. Am J Physiol 276:G1153-G1164. (Pubitemid 29251914)
35. Ohtsuka, H., Abe, T., Onogawa, T., Kondo, N., Sato, T., Oshio, H., et al. (2006). Farnesoid X receptor, hepatocyte nuclear factors 1alpha and 3beta are essential for transcriptional activation of the liver-specifc organic anion transporter-2 gene. J Gastroenterol 41:369-377.
36. Rowland, M., Toze, T. N. (1995). Clinical pharmacokinetics: concepts and application. Williams &Wilkins: Baltimore, USA.
37. Sathirakul, K., Suzuki, H., Yasuda, K., Hanano, M., Sugiyama, Y. (1993a). Construction of a physiologically based pharmacoki-netic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular difusion. Biol Pharm Bull 16:273-279.
38. Sathirakul, K., Suzuki, H., Yasuda, K., Hanano, M., Tagaya, O., Horie, T., et al. (1993b). Kinetic analysis of hepatobiliary transport of organic anions in Eisai-hyperbilirubinemic mutant rats. J Pharmacol Exp Ter 265:1301-1312.
39. Shitara, Y., Itoh, T., Sato, H., Li, A. P., Sugiyama, Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ter 304:610-616.
40. Shitara, Y., Nagamatsu, Y., Wada, S., Sugiyama, Y., Horie, T. (2009). Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metab Dispos 37:1172-1178.
41. Takane, H, Miyata, M, Burioka, N, Shigemasa, C, Shimizu, E, Otsubo, K et al. (2006). Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 51:822-826.
42. Tian, X., Swift, B., Zamek-Gliszczynski, M. J., Belinsky, M. G., Kruh, G. D., Brouwer, K. L. (2008). Impact of basolateral multid-rug resistance-associated protein (Mrp) 3 and Mrp4 on the hepa-tobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 36:911-915.
43. Tipping, E., Ketterer, B. (1981). Te infuence of soluble binding proteins on lipophile transport and metabolism in hepatocytes. Biochem J 195:441-452.
44. Ueda, K., Kato, Y., Komatsu, K., Sugiyama, Y. (2001). Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ter 297:1036-1043.
45. Urquhart, B. L., Tirona, R. G., Kim, R. B. (2007). Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578.
46. Vavricka, S. R., Van Montfoort, J., Ha, H. R., Meier, P. J., Fattinger, K. (2002). Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
47. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., Sugiyama, Y. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ter 328:652-662.
48. Yamazaki, M., Kobayashi, K., Sugiyama, Y. (1996). Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai-hyperbilirubinemic rats. Biopharm Drug Dispos 17:607-621. (Pubitemid 26319898)
49. -/- mice. J Pharmacol Exp Ter 319:1485-1491.
50. Zelcer, N., van de Wetering, K., Hillebrand, M., Sarton, E., Kuil, A., et al. (2005). Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci USA 102:7274-7279.